Save up to 30% on Elsevier print and eBooks with free shipping. No promo code needed.
Save up to 30% on print and eBooks.
Systemic Lupus Erythematosus
Basic, Applied and Clinical Aspects
1st Edition - December 23, 2015
Editor: George C. Tsokos
Language: English
eBook ISBN:9780128020098
9 7 8 - 0 - 1 2 - 8 0 2 0 0 9 - 8
Systemic Lupus Erythematosus combines basic science with clinical science to provide a translational treatment of the disease and is a useful reference for specialists in the diagn…Read more
Purchase options
LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Systemic Lupus Erythematosus combines basic science with clinical science to provide a translational treatment of the disease and is a useful reference for specialists in the diagnosis and management of patients with SLE, a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease and a reference work for hospital libraries.
Provides the very latest overview of the pathogenesis of SLE
Distills current understanding of the cellular, molecular, genetic and environmental factors that instigate and drive the disease
Includes comprehensive coverage of clinical features, including fatigue, organ system manifestations, overlap syndromes, infections, and more
Conveys the very latest understanding of mechanisms of tissue damage, including immune complexes, antibodies, and other mechanisms that lead to organ damage
Discusses the latest treatment options on disease modifying or disease controlling agents
Provides 'one stop' coverage of all the latest scientific and clinical developments in SLE
researchers in basic, applied, and clinical immunology
Dedication
List of Contributors
Introduction
Part I. Epidemiology and Diagnosis
Chapter 1. History of Systemic Lupus Erythematosus
Chapter 2. The Patient
Improve the Interactions with Your Patients
Improving Compliance
Common Pitfalls
Disability
Patient Education
The Lupus Secrets
Chapter 3. Epidemiology
Summary
Introduction
Incidence and Prevalence
Factors that Affect the Course of SLE
Mortality and Survival in SLE
Chapter 4. Measuring Disease Activity
Summary
Chapter 5. Disease Development and Outcomes
Historical Perspective
Clinical Manifestations
Assessment of Disease Activity
Disease Damage
Patient-Reported Outcomes
Mortality
Causes of Death
Treatment Guidelines and Quality Indicators
Conclusions
Chapter 6. Socioeconomic Aspects of Systemic Lupus Erythematosus
Summary
Definition and Measures of Socioeconomic Status
Problems with Measuring SES in Health Research
Impact of SES on Systemic Lupus Erythematosus Outcomes
Disease Activity
Damage Accrual
Disability
Mortality
Conclusions
Chapter 7. Biomarkers in Systemic Lupus Erythematosus
Introduction
Biomarker Definition and Validation
Biomarkers for Diagnosis of SLE
Biomarkers for Measuring SLE Disease Activity
Biomarkers to Detect Specific Organ Involvement
Genetic Susceptibility and Theranostics
Conclusions
Part II. Pathogenesis
Chapter 8. Overview of the Pathogenesis of Systemic Lupus Erythematosus
Genetic Predisposition
Epigenetic Contributions
Gender
Environment
Immune Abnormalities in SLE
Tissue Damage
Conclusions
Chapter 9. Systemic Lupus Erythematosus and the Environment
Introduction
Infectious Agents, the Microbiome, and SLE
Cigarette Smoking and SLE
Exposure to Chemicals and Risk of SLE
Ultraviolet Radiation, Vitamin D, and SLE
Drugs, Vaccines, and SLE
Conclusion
Chapter 10. Genes and Genetics in Human Systemic Lupus Erythematosus
Introduction
SLE-Risk Genes in Immunological Pathways
SLE-Risk Genes with Other Functions
Genes Connected to Phenotypes in SLE
Conclusion and Future Directions
Chapter 11. Hormones
Sex Hormones
Hormones and the Immune Response
Hormone Receptors
Hormone Therapy
Chapter 12. The Complement System in Systemic Lupus Erythematosus
Introduction
Complement Testing and its Interpretations
Immunology and Genetics of Early Complement Components of the Classical Pathway
Complement Receptors and Regulators in SLE
Autoantibodies to Complement and Acquired Deficiency of Complement in SLE
New Connections for Lupus and Complement
Conclusions
Chapter 13. T Cells
Mechanisms through Which T Cells Promote SLE
Pro-inflammatory Activities
Signaling and Gene Expression in SLE T Cells
Chapter 14. Integrating Current Thinking on Peripheral B-Cell Tolerance in Lupus
B-Cell Depletion Therapy, Regulatory B Cells, and Lupus
The Type I Interferon Pathway in Lupus and a Potential Link to Immune Tolerance
Complement Function, Apoptotic Cell Clearance, and Lupus
Increased BAFF in Lupus: A Contributor to a Break in Tolerance or Consequence of Inflammation?
Chapter 15. Neutrophils in Systemic Lupus Erythematosus
Introduction
Neutrophil Dysfunction in SLE
NETosis in the Pathogenesis of SLE
Low-Density Granulocytes in SLE
DNA Methylation Changes in SLE Neutrophils and LDGs
Conclusion
Chapter 16. The Role of Dendritic Cells in Systemic Lupus Erythematosus
Dendritic Cell Origins, Subsets, and Functions
DCs and SLE
Overall Picture of DC Implication in SLE Pathogenesis
Amplifying Mechanisms Promoting IFN-α Secretion in SLE and Activation of DCs
Prevalence and Associated Features of Vasculitis in Lupus
Cutaneous Vasculitis
Lupus Mesenteric Vasculitis
Large Vessel Vasculitis
Other Forms of Vasculitis
Part V. Antiphospholipid Syndrome
Chapter 56. Pathogenesis of Antiphospholipid Syndrome
Introduction
Pathogenesis of aPL
Interaction of aPL with Cells
Conclusion
Chapter 57. Antibodies and Diagnostic Tests in Antiphospholipid Syndrome
Summary
Antiphospholipid Syndrome as an Autoantibody-Mediated Disease
Classification Laboratory Assays
Nonclassification Laboratory Assays
Other Autoantibodies in Antiphospholipid Syndrome
Chapter 58. Clinical Manifestations
Summary
Introduction
Vascular Thrombosis
Pregnancy Morbidity
Catastrophic APS
Features Associated with aPL
Part VI. Treatment of the Disease
Chapter 59. Nonsteroidal Anti-inflammatory Drugs in Systemic Lupus Erythematosus
Introduction
Inhibitory Role of NSAIDs
Effects on the Kidneys
Gastrointestinal Side Effects
Increased Cardiovascular Risk: What Is the Verdict?
Central Nervous System (Aseptic Meningitis) Side Effects
Effects on Reproduction
Conclusion
Chapter 60. Value of Antimalarial Drugs in the Treatment of Lupus
Introduction
Pharmacokinetics and Pharmacodynamics of Antimalarials
Mechanisms of Action
The Beneficial Effects of Antimalarials in SLE
Practical Aspects Related to the Use of Antimalarials
Screening for Glucose-6-Phosphate Dehydrogenase Deficiency
Nonophthalmologic Adverse Effects of Antimalarial Agents
Ophthalmologic Adverse Effects of Antimalarial Agents
Use of Antimalarials in Pregnancy and Lactation
Chapter 61. Systemic Glucocorticoids
Introduction
Nomenclature
Rationale and Mechanism of Action of Glucocorticoids in SLE
Forms and Mode of Administration of Systemic Corticosteroids
Approach to the Use of Glucocorticoids Based on Organ System Involvement
Tapering and Withdrawal of Glucocorticoids
Side Effects of Corticosteroids
Future Direction
Chapter 62. Cytotoxic-Immunosuppressive Drug Treatment
Summary
Introduction
Alkylating Agents
Nucleotide Synthesis Inhibitors
Calcineurin Inhibitors
General Issues in Lupus Patients on Cytotoxic/Immunosuppressive Drug Treatment
Chapter 63. Treatment of Antiphospholipid Syndrome
Introduction
Primary Thromboprophylaxis
Prevention of Recurrent Thrombosis
Alternative Therapies for Refractory and Difficult Cases
Other Therapies
Pregnancy
Recurrent Early Miscarriage
Fetal Death
Management of Pregnancy in Patients with APS and Previous Thrombosis
Management of Refractory Obstetric APS
Postpartum Period
Chapter 64. New Treatments for Systemic Lupus Erythematosus
Summary
Cytokines
Complement
Co-Stimulatory Pathways
Cell Surface Molecules
Conclusion
Chapter 65. Management Lessons from Clinical Trials of Kidney Disease in Systemic Lupus Erythematosus
Summary
Kidney Disease in Systemic Lupus Erythematosus
Patient Selection in Clinical Trials
End points for Clinical Trials
Matching Clinical Trial Expectations to the Experimental Therapeutic
Conclusion
Chapter 66. Repositioning Drugs for Systemic Lupus Erythematosus
Why Try to Repurpose Drugs for SLE Patients?
LRxL-STATTM: Repositioning Treatments for SLE Patients
Identification of Top Priority LRxL-STATTM Candidates
Summary
Appendix
Index
No. of pages: 640
Language: English
Edition: 1
Published: December 23, 2015
Imprint: Academic Press
eBook ISBN: 9780128020098
GT
George C. Tsokos
George C. Tsokos, MD, is a Professor of Medicine at Harvard Medical School and Chief of Rheumatology and Clinical Immunology at Beth Israel Deaconess Medical Center. Dr Tsokos has served as President of the Clinical Immunology Society, on the boards of directors for the American College of Rheumatology and the Lupus Foundation of America, member/chair of multiple federal study sections, and editor/member of the editorial boards for top scientific journals. He has received several awards, including a MERIT from NIH, the Lee C. Howley Sr. Prize, the Evelyn V. Hess, the Distinguished Basic Investigator Award from the American College of Rheumatology, the Lupus Insight Prize from the Lupus Research Alliance, and the Carol Nachman Prize for Rheumatology. He is a Master of the American College of Physicians and the American College of Rheumatology, a member of American Association of Physicians and Fellow of AAAS.
Affiliations and expertise
Professor of Medicine at Harvard Medical School and Chief of Rheumatology and Clinical Immunology at Beth Israel Deaconess Medical Center